medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-35-100-107medalphabet-4140Research ArticleСтатьиРоль Acinetobacter baumanii в этиологии нозокомиальных инфекций и возможные варианты рациональной антибиотикотерапии у взрослых и детейThe role of Acinetobacter baumanii in the etiology of nosocomial infections and possible options for rational antibiotic therapy in adults and childrenhttps://orcid.org/0000-0003-4259-0945ТепловаН. В.TeplovaN. V.

Теплова Наталья Вадимовна, д. м. н., профессор, зав. кафедрой клинической фармакологии Лечебного факультета

Москва

Teplova Natalia V., DM Sci (habil.), professor, head of Dept of Clinical Pharmacology of Faculty of Medicine

Moscow

teplova.nv@yandex.ruhttps://orcid.org/0000-0001-8468-6959ПостниковС. С.PostnikovS. S.

Постников Сергей Сергеевич, д. м. н., профессор кафедры клинической фармакологии Лечебного факультета

Москва

Postnikov Sergey S., DM Sci (habil.), professor at Dept of Clinical Pharmacology of Faculty of Medicine

Moscow

elixin@list.ruhttps://orcid.org/0000-0002-7656-1539РумянцевА. Л.RumyancevA. L.

Румянцев Александр Львович, к. м. н., зав. отделением гемодиализа

Москва

Rumyancev Alexander L., PhD Med, head of Hemodialysis Dept

Moscow

rumalex1967@gmail.comhttps://orcid.org/0000-0002-7656-1539КостылеваМ. Н.KostylevaM. N.

Костылева Мария Николаевна, к. м. н., доцент кафедры клинической фармакологии Лечебного факультета;

зав. отделением клинической фармакологии

Москва

Kostyleva Maria N., PhD Med, associate professor at Dept of Clinical Pharmacology of Faculty of Medicine;

head of Dept of Clinical Pharmacology

Moscow

kostyleva_m_n@rdkb.ruГрацианскаяА. Н.GratsianskayaA. N.

Грацианская Анна Николаевна, к. м. н., доцент кафедры клинической фармакологии Лечебного факультета

Москва

Gratsianskaya Anna N., PhD Med, associate professor at Dept of Clinical Pharmacology of Faculty of Medicine

Moscow

annagrats@rambler.ruhttps://orcid.org/0009-0007-9130-3267БелоусоваЛ. Б.BelousovaL. B.

Белоусова Людмила Борисовна, студентка 6-го курса педиатрического факультета

Москва

Belousova Lyudmila B., 6th-year student of Pediatric Faculty

Moscow

lubelousova@mail.ruhttps://orcid.org/0009-0009-9118-6122ДалакянД. Ю.DalakyanD. Yu.

Далакян Дарья Юрьевна, студентка 6-го курса педиатрического факультета

Москва

Dalakyan Daria Yu., 6th year student of Pediatric Faculty

Moscow

ddy2310@gmail.comКафедра клинической фармакологии им. Ю. Б. Белоусова ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РоссииРоссияDept of Clinical Pharmacology named after Yu. B. Belousov at N. I. Pirogov Russian National Research Medical UniversityRussian FederationРоссийская детская клиническая больница – филиал ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РоссииРоссияRussian Children's Clinical Hospital – branch of N. I. Pirogov Russian National Research Medical UniversityRussian FederationКафедра клинической фармакологии им. Ю. Б. Белоусова ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава России; Российская детская клиническая больница – филиал ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РоссииРоссияDept of Clinical Pharmacology named after Yu. B. Belousov at N. I. Pirogov Russian National Research Medical University; Russian Children's Clinical Hospital – branch of N. I. Pirogov Russian National Research Medical UniversityRussian Federation202423012025035Кардиология. Неотложная медицина (4)100107Copyright © Теплова Н.В., Постников С.С., Румянцев А.Л., Костылева М.Н., Грацианская А.Н., Белоусова Л.Б., Далакян Д.Ю., 20252025Теплова Н.В., Постников С.С., Румянцев А.Л., Костылева М.Н., Грацианская А.Н., Белоусова Л.Б., Далакян Д.Ю.Teplova N.V., Postnikov S.S., Rumyancev A.L., Kostyleva M.N., Gratsianskaya A.N., Belousova L.B., Dalakyan D.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4140

В середине XX века и позже основную бактериальную угрозу в стационаре представляли грамположительные инфекции, при этом ведущую роль играл стафилококк («стафилококковая чума»). В последние 20 лет произошла эволюция, смена флоры и теперь уже грамотрицательные инфекции, особенно триада (A. baumanii, K. pneumoniae, P. aeruginosa) из группы ESCAPE, определяют заболеваемость и смертность в стационаре вследствие растущей резистентности к карбапенемам и цефалоспоринам и, соответственно, ограниченности выбора. В обзоре, касающемся возможностей лечения A. baumanii у взрослых и детей (прежде всего грудного возраста и новорожденных) рассмотрены варианты антибиотикотерапии.

In the mid‑20th century and later, the main bacterial threat in hospitals was gram-positive infections, with staphylococcus aureus (“staphylococcal plague”) playing the leading role. In the last 20 years, there has been an evolution, a change in flora, and now gram-negative infections, especially the triad (A. baumanii, K. pneumoniae, P. aeruginosa) from the ESCAPE group, determine hospital morbidity and mortality due to increasing resistance to carbapenems and cephalosporins and, accordingly, limited choice. In the review concerning the treatment options for A. baumanii in adults and children (especially infants and neonates), antibiotic therapy options are considered.

Acinetobacter baumaniiколистиннефротоксичностьвзрослыеноворожденныеAcinetobacter baumaniicolistinnephrotoxicityadultsneonatesReferencesСидоренко С. В. Проблема антибиотикорезистентности: причины и возможности преодоления // Участковый терапевт. 2014. № . 1. С. 20–21.Sidorenko S. V. The problem of antibiotic resistance: causes and ways to overcome it // District therapist. 2014. No. 1. P. 20–21. (In Russ.).Ортенберг Э. А., Голуб А. В. Цефотаксим/сульбактам: клинико-фармакологическая характеристика // Клиническая микробиология и антимикробная химиотерапия. 2019. Т. 21. № . 3. С. 212–216.Ortenberg E. A., Golub A. V. Cefotaxime / sulbactam: clinical and pharmacological characteristics // Clinical microbiology and antimicrobial chemotherapy. 2019. Vol. 21. No. 3. P. 212–216. (In Russ.).Яковлев С. В. Современные подходы к лечению грамположительных инфекций: что нового? // XXI Российская конференция «Современные проблемы и перспективы антимикробной терапии». Материалы и тезисы 15–16 ноября. 2019. С. 8–13.Yakovlev S. V. Modern approaches to the treatment of gram-positive infections: what’s new? // XXI Russian Conference «Modern Problems and Prospects of Antimicrobial Therapy». Materials and Abstracts November 15–16. 2019. P. 8–13. (In Russ.).Полякова Е. М., Божкова С. А., Иванникова Ю. Г., Губанова А. Б., Водольянова Г. А. Сравнение клинических изолятов K. pneumonia, P. aeruginosa и Acinetobacter spp. по чувствительности к имипенему, меропенему, дорипенему //Клиническая микробиология и антимикробная химиотерапия. 2017. Т. 19. № . S 1 – С. 13.Polyakova E. M., Bozhkova S. A., Ivannikova Yu.G., Gubanova A. B., Vodolyanova G. A. Comparison of clinical isolates of K. pneumonia, P. aeruginosa and Acinetobacter spp. by susceptibility to imipenem, meropenem, doripenem // Clinical microbiology and antimicrobial chemotherapy. 2017. Vol. 19. No. S 1 P. 13. (In Russ.).Орлова Е. С., Суборова Т. Н., Свистунов С. А. и соавт. Спектр возбудителей раневых инфекций у пациентов многопрофильного хирургического стационара // Клиническая микробиология и антимикробная химиотерапия. 2017. Т. 19. № . S 1 – С. 32.Orlova E. S., Suborova T. N., Svistunov S. A. et al. Spectrum of pathogens of wound infections in patients of a multidisciplinary surgical hospital // Clinical microbiology and antimicrobial chemotherapy. 2017. Vol. 19. No. S 1 – P. 32. (In Russ.).Şimşek F. et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? // Indian journal of medical microbiology. 2012. Т. 30. № . 4. С. 448–452.Şimşek F. et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? // Indian journal of medical microbiology. 2012. Т. 30. № . 4. С. 448–452.Nakwan N., Chokephaibulkit K., Imberti R. The use of colistin for the treatment of multidrug-resistant Gram-negative infections in neonates and infants: a review of the literature //The Pediatric Infectious Disease Journal. 2019. Т. 38. № . 11. С. 1107–1112.Nakwan N., Chokephaibulkit K., Imberti R. The use of colistin for the treatment of multidrug-resistant Gram-negative infections in neonates and infants: a review of the literature //The Pediatric Infectious Disease Journal. 2019. Т. 38. № . 11. С. 1107–1112.Weinberg S. E. et al. Control and management of multidrug resistant Acinetobacter baumannii: A review of the evidence and proposal of novel approaches // Infection Prevention in Practice. 2020. Т. 2. № . 3. С. 100077.Weinberg S. E. et al. Control and management of multidrug resistant Acinetobacter baumannii: A review of the evidence and proposal of novel approaches // Infection Prevention in Practice. 2020. Т. 2. № . 3. С. 100077.Захарова Ю. А., С. В. Сидоренко, Н. А. Маянский и соавт. Мультилокусное сиквенс-типирование полирезистентных Acinobacter Baumannii и Staphylococcus Aureus, циркулирующих в сомато-психиатрическом отделении //Клиническая микробиология и антимикробная химиотерапия. 2017. Т. 19. № . S 1. С. 19–20.Zakharova Yu. A., S. V. Sidorenko, N. A. Mayansky et al. Multilocus sequence typing of multidrug-resistant Acinobacter Baumannii and Staphylococcus Aureus circulating in the somato-psychiatric department // Clinical Microbiology and Antimicrobial Chemotherapy. 2017. Vol. 19. No. S 1. P. 19–20. (In Russ.).Лавриненко А. В., Колесниченко С. Н., Захарова Е. А. и соавт. Антибиотикорезистентность неферментирующих грамотрицательных микроорганизмов, выделенных в стационарах центрального Казахстана // Клиническая микробиология и антимикробная химиотерапия. 2017. Т. 19. № . S 1. С. 26.Lavrinenko A. V., Kolesnichenko S. N., Zakharova E. A. et al. Antibiotic resistance of non-fermenting gram-negative microorganisms isolated in hospitals of central Kazakhstan // Clinical Microbiology and Antimicrobial Chemotherapy. 2017. Vol. 19. No. S 1. P. 26. (In Russ.).Мелкумян А. Р., Цыбин А. Н., Латыпова М. Ф., Иванушкина О. И., Стребков В. Г. Анализ результатов микробиологического мониторинга в медицинских организациях г. Москвы // Клиническая микробиология и антимикробная химиотерапия. 2017. Т. 19. № . S 1. С. 29.Melkumyan A. R., Tsybin A. N., Latypova M. F., Ivanushkina O. I., Strebkov V. G. Analysis of the results of microbiological monitoring in medical organizations of Moscow // Clinical microbiology and antimicrobial chemotherapy. 2017. Vol. 19. No. S 1. P. 29. (In Russ.).Ng D. H. L. et al. Environmental colonization and onward clonal transmission of carbapenem-resistant Acinetobacter baumannii (CRAB) in a medical intensive care unit: the case for environmental hygiene //Antimicrobial Resistance & Infection Control. 2018. Т. 7. № . 1. С. 1–8.Ng D. H. L. et al. Environmental colonization and onward clonal transmission of carbapenem-resistant Acinetobacter baumannii (CRAB) in a medical intensive care unit: the case for environmental hygiene //Antimicrobial Resistance & Infection Control. 2018. Т. 7. № . 1. С. 1–8.Wong D. et al. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges //Clinical microbiology reviews. 2017. Т. 30. № . 1. С. 409–447.Wong D. et al. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges //Clinical microbiology reviews. 2017. Т. 30. № . 1. С. 409–447.Viehman J. A., Nguyen M. H., Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections //Drugs. 2014. Т. 74. С. 1315–1333.Viehman J. A., Nguyen M. H., Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections //Drugs. 2014. Т. 74. С. 1315–1333.Alrahmany D. et al. Acinetobacter baumannii infections in hospitalized patients, treatment outcomes // Antibiotics. 2021. Т. 10. № . 6. С. 630.Alrahmany D. et al. Acinetobacter baumannii infections in hospitalized patients, treatment outcomes // Antibiotics. 2021. Т. 10. № . 6. С. 630.Rodrigues D. L. N. et al. Acinetobacter baumannii and Its relationship to carbapenem resistance: a meta-analysis //Bacteria. 2022. Т. 1. № . 2. С. 112–120.Rodrigues D. L. N. et al. Acinetobacter baumannii and Its relationship to carbapenem resistance: a meta-analysis //Bacteria. 2022. Т. 1. № . 2. С. 112–120.Karakonstantis S., Saridakis I. Colistin heteroresistance in Acinetobacter spp.: Systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications //International journal of antimicrobial agents. 2020. Т. 56. № . 2. С. 106065.Karakonstantis S., Saridakis I. Colistin heteroresistance in Acinetobacter spp.: Systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications //International journal of antimicrobial agents. 2020. Т. 56. № . 2. С. 106065.Karakonstantis S., Kritsotakis E. I., Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems // Infection. 2020. Т. 48. № . 6. С. 835–851.Karakonstantis S., Kritsotakis E. I., Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems // Infection. 2020. Т. 48. № . 6. С. 835–851.Яковлев С. В. Значение ингибиторзащищенных бета-лактамов в клинике // XXI Российская конференция «Современные проблемы и перспективы антимикробной терапии». Материалы и тезисы 15–16 ноября. 2019. С. 48–54.Yakovlev S. V. The importance of inhibitor-protected beta-lactams in the clinic // XXI Russian conference «Modern problems and prospects of antimicrobial therapy». Materials and abstracts of November 15–16. 2019. P. 48–54. (In Russ.).Huang C., Chen I., Tang T. Colistin monotherapy versus colistin plus meropenem combination therapy for the treatment of multidrug-resistant Acinetobacter baumannii infection: a meta-analysis // Journal of clinical medicine. 2022. Т. 11. № . 11. С. 3239.Huang C., Chen I., Tang T. Colistin monotherapy versus colistin plus meropenem combination therapy for the treatment of multidrug-resistant Acinetobacter baumannii infection: a meta-analysis // Journal of clinical medicine. 2022. Т. 11. № . 11. С. 3239.Kengkla K. et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis //Journal of Antimicrobial Chemotherapy. 2018. Т. 73. № . 1. С. 22–32.Kengkla K. et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis //Journal of Antimicrobial Chemotherapy. 2018. Т. 73. № . 1. С. 22–32.Durante-Mangoni E. et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial //Clinical infectious diseases. 2013. Т. 57. № . 3. С. 349–358.Durante-Mangoni E. et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial //Clinical infectious diseases. 2013. Т. 57. № . 3. С. 349–358.Al-Mouqdad M. et al. Safety and efficacy of colistin and fluoroquinolone in neonatal persistent late-onset sepsis //Saudi Pharmaceutical Journal. 2021. Т. 29. № . 9. С. 1013–1020.Al-Mouqdad M. et al. Safety and efficacy of colistin and fluoroquinolone in neonatal persistent late-onset sepsis //Saudi Pharmaceutical Journal. 2021. Т. 29. № . 9. С. 1013–1020.Jajoo M. et al. Intravenous colistin administration in neonates //The Pediatric infectious disease journal. 2011. Т. 30. № . 3. С. 218–221.Jajoo M. et al. Intravenous colistin administration in neonates //The Pediatric infectious disease journal. 2011. Т. 30. № . 3. С. 218–221.Rosanova M. et al. Use of colistin in a pediatric burn unit in Argentina //Journal of burn care & research. 2009. Т. 30. № . 4. С. 612–615.Rosanova M. et al. Use of colistin in a pediatric burn unit in Argentina //Journal of burn care & research. 2009. Т. 30. № . 4. С. 612–615.Terayama T. et al. Polymyxin B hemoperfusion for sepsis and septic shock: a systematic review and meta-analysis //Surgical Infections. 2017. Т. 18. № . 3. С. 225–233.Terayama T. et al. Polymyxin B hemoperfusion for sepsis and septic shock: a systematic review and meta-analysis //Surgical Infections. 2017. Т. 18. № . 3. С. 225–233.Ritchie D. J., Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections //Clinical infectious diseases. 2014. Т. 59. № . suppl_6. С. S 374-S 380.Ritchie D. J., Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections //Clinical infectious diseases. 2014. Т. 59. № . suppl_6. С. S 374-S 380.Sirijatuphat R., Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections //Antimicrobial agents and chemotherapy. 2014. Т. 58. № . 9. С. 5598–5601.Sirijatuphat R., Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections //Antimicrobial agents and chemotherapy. 2014. Т. 58. № . 9. С. 5598–5601.Ilhan O. et al. Efficacy and safety of intravenous colistin in very low birth weight preterm infants / Pediatric Drugs. 2018. Т. 20. С. 475–481.Ilhan O. et al. Efficacy and safety of intravenous colistin in very low birth weight preterm infants / Pediatric Drugs. 2018. Т. 20. С. 475–481.Kapoor K. et al. Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients //Pediatric Critical Care Medicine. 2013. Т. 14. № . 6. С. e268-e272.Kapoor K. et al. Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients //Pediatric Critical Care Medicine. 2013. Т. 14. № . 6. С. e268-e272.Falagas M. E. et al. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis //The Pediatric infectious disease journal. 2009. Т. 28. № . 2. С. 123–127.Falagas M. E. et al. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis //The Pediatric infectious disease journal. 2009. Т. 28. № . 2. С. 123–127.Zavascki A. P., Nation R. L. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? //Antimicrobial agents and chemotherapy. 2017. Т. 61. № . 3. С. 10.1128/aac.02319–16.Zavascki A. P., Nation R. L. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? //Antimicrobial agents and chemotherapy. 2017. Т. 61. № . 3. С. 10.1128/aac.02319–16.Urban C., Mariano N., Rahal J. J. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli //Antimicrobial agents and chemotherapy. 2010. Т. 54. № . 6. С. 2732–2734.Urban C., Mariano N., Rahal J. J. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli //Antimicrobial agents and chemotherapy. 2010. Т. 54. № . 6. С. 2732–2734.Karakonstantis S. et al. Systematic review of antimicrobial combination options for pandrug-resistant Acinetobacter baumannii //Antibiotics. 2021. Т. 10. № . 11. С. 1344.Karakonstantis S. et al. Systematic review of antimicrobial combination options for pandrug-resistant Acinetobacter baumannii //Antibiotics. 2021. Т. 10. № . 11. С. 1344.Karakonstantis S., Kritsotakis E. I. Editorial for the Special Issue:“Epidemiology, Prognosis and Antimicrobial Treatment of Extensively Antibiotic-Resistant Bacterial Infections” //Antibiotics. 2022. Т. 11. № . 6. С. 804.Karakonstantis S., Kritsotakis E. I. Editorial for the Special Issue:“Epidemiology, Prognosis and Antimicrobial Treatment of Extensively Antibiotic-Resistant Bacterial Infections” //Antibiotics. 2022. Т. 11. № . 6. С. 804.Яковлев С. В. предпосылки к изменению подходов к антибактериальной терапии нозокомиальных инфекций в ОРИТ //XXI Российская конференция «Современные проблемы и перспективы антимикробной терапии». Материалы и тезисы 15–16 ноября. 2019. С. 18–23.Yakovlev S. V. prerequisites for changing approaches to antibacterial therapy of nosocomial infections in intensive care units // XXI Russian Conference «Modern Problems and Prospects of Antimicrobial Therapy». Proceedings and Abstracts November 15–16. 2019. P. 18–23. (In Russ.).Shi J. et al. Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit //BMC Infectious Diseases. 2020. Т. 20. С. 1–9.Shi J. et al. Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit //BMC Infectious Diseases. 2020. Т. 20. С. 1–9.Kalin G. et al. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia // Infection. 2014. Т. 42. С. 37–42.Kalin G. et al. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia // Infection. 2014. Т. 42. С. 37–42.Яковлев С. В., Суворова М. П. Цефотаксим/сульбактам: важное пополнение в арсенале ингибиторозащищённых бета-лактамных антибиотиков // Антибиотики и химиотерапия. 2019. Т. 64. № . 3–4. С. 70–80.Yakovlev S. V., Suvorova M. P. Cefotaxime / sulbactam: an important addition to the arsenal of inhibitor-protected beta-lactam antibiotics // Antibiotics and chemotherapy. 2019. V. 64. No. 3–4. P. 70–80. (In Russ.).Суворова М. П. Опыт применения ингибиторзащищенных цефалоспоринов в качестве карбапенем-сберегающих технологий //XXI Российская конференция «Современные проблемы и перспективы антимикробной терапии». Материалы и тезисы 15–16 ноября. 2019. С. 56–61.Suvorova M. P. Experience in using inhibitor-protected cephalosporins as carbapenem-sparing technologies // XXI Russian Conference «Modern Problems and Prospects of Antimicrobial Therapy». Materials and abstracts of November 15–16. 2019. P. 56–61. (In Russ.).Chan P. C. et al. Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit //Infection Control & Hospital Epidemiology. 2007. Т. 28. № . 4. С. 423–429.Chan P. C. et al. Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit //Infection Control & Hospital Epidemiology. 2007. Т. 28. № . 4. С. 423–429.Hsu J. F. et al. Case-control analysis of endemic Acinetobacter baumannii bacteremia in the neonatal intensive care unit //American journal of infection control. 2014. Т. 42. № . 1. С. 23–27.Hsu J. F. et al. Case-control analysis of endemic Acinetobacter baumannii bacteremia in the neonatal intensive care unit //American journal of infection control. 2014. Т. 42. № . 1. С. 23–27.Al Jarousha A. M. K. et al. Nosocomial multidrug-resistant Acinetobacter baumannii in the neonatal intensive care unit in Gaza City, Palestine //International Journal of Infectious Diseases. 2009. Т. 13. № . 5. С. 623–628.Al Jarousha A. M. K. et al. Nosocomial multidrug-resistant Acinetobacter baumannii in the neonatal intensive care unit in Gaza City, Palestine //International Journal of Infectious Diseases. 2009. Т. 13. № . 5. С. 623–628.Al-Mouqdad M. et al. Safety and efficacy of colistin and fluoroquinolone in neonatal persistent late-onset sepsis //Saudi Pharmaceutical Journal. 2021. Т. 29. № . 9. С. 1013–1020.Al-Mouqdad M. et al. Safety and efficacy of colistin and fluoroquinolone in neonatal persistent late-onset sepsis //Saudi Pharmaceutical Journal. 2021. Т. 29. № . 9. С. 1013–1020.Tekgunduz K. S. et al. Safety and efficacy of intravenous colistin in neonates with culture proven sepsis //Iranian journal of pediatrics. 2015. Т. 25. № . 4.Tekgunduz K. S. et al. Safety and efficacy of intravenous colistin in neonates with culture proven sepsis //Iranian journal of pediatrics. 2015. Т. 25. № . 4.Nakwan N. et al. Pharmacokinetics of colistin following a single dose of intravenous colistimethate sodium in critically ill neonates //The Pediatric infectious disease journal. 2016. Т. 35. № . 11. С. 1211–1214.Nakwan N. et al. Pharmacokinetics of colistin following a single dose of intravenous colistimethate sodium in critically ill neonates //The Pediatric infectious disease journal. 2016. Т. 35. № . 11. С. 1211–1214.Celebi S. et al. Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients // Pediatrics International. 2010. Т. 52. № . 3. С. 410–414.Celebi S. et al. Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients // Pediatrics International. 2010. Т. 52. № . 3. С. 410–414.Cakir U. et al. Acquired bartter-like syndrome associated with colistin use in a preterm infant //Renal Failure. 2013. Т. 35. № . 3. С. 411–413.Cakir U. et al. Acquired bartter-like syndrome associated with colistin use in a preterm infant //Renal Failure. 2013. Т. 35. № . 3. С. 411–413.Yurttutan S., Atalay B. C. Short and long term side effect of colistin treatment in preterm infants // The Turkish Journal of Pediatrics. 2021. Т. 63. № . 6. С. 1108–1109.Yurttutan S., Atalay B. C. Short and long term side effect of colistin treatment in preterm infants // The Turkish Journal of Pediatrics. 2021. Т. 63. № . 6. С. 1108–1109.

The authors declare that there are no conflicts of interest present.